Deaths / year
40,000
GBD (indicative unless refreshed)
DALYs / year
2,900,000
GBD
Pathogen
Virus
Post-infectious
Post-infectious syndrome
Persistent symptoms
~20%
confirmed dengue patients
WHO groups dengue+chikungunya as one NTD entry; split here.
Post-infectious syndrome & persistent symptoms
Whether a post-acute infection syndrome is documented and the literature proportion with persistent symptoms.
Documented post-infectious syndrome
Post-dengue / post-infectious fatigue
~20%
persistent symptoms — of confirmed dengue patients
Summary
Pooled post-infectious fatigue 20% (95% CI 10-36%); single cohorts 25% (Seet 2007) and 32.3% at 2 months (Colombo 2021).
Timeframe
weeks to months post-acute
Evidence strength
moderate-strong
Classification
Post-infectious syndrome
Sources: eClinicalMedicine 2024 meta-analysis (PIF 20%); Seet 2007 (25%); Colombo Dengue Study 2021 (32.3%)
Therapeutic agents by stage
Vector control, prevention, acute treatment, and post-infectious care. Only agents with published evidence are shown by default.
Vector & transmission control
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Aedes aegypti / albopictus source reduction | Vector control | Approved | Eliminate breeding sites; community mobilization | WHO dengue guidelines |
| Larvicides (temephos, Bacillus thuringiensis israelensis) | Vector control | Approved | Treat water-storage containers and habitats | WHO |
| Wolbachia-infected mosquito deploymentPipeline | Vector control | Phase 3 | Population replacement reduces dengue transmission | Published field trials; WHO/TDR |
Prevention
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Personal repellents & protective clothing | Prevention | Approved | Reduce Aedes exposure during outbreaks | WHO EML / standard of care |
| Dengue tetravalent vaccine (Qdenga/TAK-003) | Vaccine | Approved | Live attenuated tetravalent dengue vaccine | WHO / approved vaccines |
| Dengvaxia (CYD-TDV) | Vaccine | Approved | Recombinant chimeric yellow fever–dengue vaccine (serostatus restrictions) | WHO SAGE |
Acute phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Supportive care (IV fluids, hemodynamic monitoring) | Supportive | Approved | No approved antiviral; fluid resuscitation for severe dengue | WHO EML / standard of care |
| Paracetamol (avoid NSAIDs & aspirin) | Supportive | Approved | Fever/analgesia without bleeding risk | WHO dengue |
| Blood component therapy | Supportive | Approved | Severe dengue hemorrhage / plasma leakage | WHO EML / standard of care |
| EMETINE HYDROCHLORIDEPipeline | Small molecule | Phase 3 | — | Open Targets (clinical pipeline) |
| MONTELUKASTPipeline | Small molecule | Phase 3 | — | Open Targets (clinical pipeline) |
| CELGOSIVIRPipeline | Small molecule | Phase 2 | — | Open Targets (clinical pipeline) |
| MODIPAFANTPipeline | Small molecule | Phase 2 | — | Open Targets (clinical pipeline) |
| METFORMINPipeline | Small molecule | Phase 2 | — | Open Targets (clinical pipeline) |
Post-infectious phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Graduated activity & fatigue rehabilitation | Rehabilitation | Approved | Post-dengue fatigue syndrome management | Seet 2007; Garcia 2011 |
Associated drug targets (Open Targets): APOA1, HAVCR1, YBX1, CD209, PROS1, HSPA5
Burden: IHME GBD (indicative seed unless refreshed) · Therapeutics: curated WHO EML / SOC + Open Targets pipeline · Post-infectious data: curated peer-reviewed literature · Ontology: MONDO_0005502 · Updated 2026-07-10. Associations, not a diagnostic test.